Premium
Age is just a number, the wrong number
Author(s) -
Bal Susan,
Costa Luciano J.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33170
Subject(s) - medicine , multiple myeloma , gerontology , hematopoietic cell , transplantation , cancer , consolidation (business) , stem cell , demography , haematopoiesis , biology , genetics , accounting , sociology , business
Despite the evolution of the therapeutic landscape of multiple myeloma, autologous hematopoietic stem cell transplantation (AHCT) continues to be complementary to novel agents, even among older patients. In this issue of Cancer , Munshi et al report the largest study supporting the role of AHCT as an effective consolidation strategy across all age groups. The future incorporation of individualized, response‐ and frailty‐adapted treatment paradigms will define the future of myeloma therapy for older adults.